A randomized, open-label, single oral dose, two-way crossover study under fasting condition. Target number of subjects: 46 subjects in total.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of BR3003 and co-administration of BR3003B and BR3003C in healthy adults.